 Evan Osmundson
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 5 | 2021 | 258 | 1.550 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2135 | 1.070 |
Why?
| | Homeless Persons | 1 | 2020 | 24 | 0.850 |
Why?
| | Leukopenia | 1 | 2020 | 65 | 0.830 |
Why?
| | Radiation Oncology | 1 | 2022 | 116 | 0.810 |
Why?
| | Neoplasms | 4 | 2021 | 2725 | 0.720 |
Why?
| | Liver Neoplasms | 4 | 2016 | 640 | 0.710 |
Why?
| | Radiation Injuries | 3 | 2016 | 159 | 0.710 |
Why?
| | Liver | 4 | 2016 | 1260 | 0.700 |
Why?
| | Esophageal Neoplasms | 1 | 2020 | 347 | 0.650 |
Why?
| | Cholangiocarcinoma | 2 | 2016 | 57 | 0.600 |
Why?
| | Bile Duct Neoplasms | 2 | 2016 | 70 | 0.590 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2015 | 60 | 0.570 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2021 | 310 | 0.550 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2016 | 322 | 0.480 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 991 | 0.480 |
Why?
| | Calcium-Binding Proteins | 1 | 2008 | 121 | 0.350 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2008 | 172 | 0.340 |
Why?
| | Radiotherapy Dosage | 4 | 2021 | 483 | 0.320 |
Why?
| | Databases, Factual | 2 | 2021 | 801 | 0.310 |
Why?
| | Cell Cycle Proteins | 1 | 2008 | 387 | 0.300 |
Why?
| | Repressor Proteins | 1 | 2008 | 409 | 0.290 |
Why?
| | Humans | 19 | 2022 | 84199 | 0.290 |
Why?
| | Uncertainty | 1 | 2021 | 58 | 0.230 |
Why?
| | Mycosis Fungoides | 1 | 2020 | 21 | 0.220 |
Why?
| | Electrons | 1 | 2021 | 50 | 0.220 |
Why?
| | Radiometry | 1 | 2021 | 50 | 0.220 |
Why?
| | Health Care Costs | 1 | 2022 | 225 | 0.200 |
Why?
| | Survival Analysis | 2 | 2021 | 1591 | 0.200 |
Why?
| | Academic Medical Centers | 1 | 2022 | 395 | 0.190 |
Why?
| | Cardiology | 1 | 2020 | 124 | 0.190 |
Why?
| | Patient Compliance | 1 | 2020 | 249 | 0.190 |
Why?
| | Bone Marrow | 1 | 2020 | 421 | 0.180 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2016 | 201 | 0.180 |
Why?
| | Physician's Role | 1 | 2020 | 187 | 0.180 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 293 | 0.170 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 468 | 0.170 |
Why?
| | Kinetics | 1 | 2020 | 1624 | 0.170 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1686 | 0.160 |
Why?
| | Nomograms | 1 | 2016 | 25 | 0.160 |
Why?
| | Bilirubin | 1 | 2016 | 129 | 0.160 |
Why?
| | Skin Neoplasms | 1 | 2020 | 545 | 0.150 |
Why?
| | Lung | 1 | 2021 | 1079 | 0.150 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1935 | 0.150 |
Why?
| | Relative Biological Effectiveness | 1 | 2015 | 14 | 0.150 |
Why?
| | DNA, Neoplasm | 1 | 2015 | 273 | 0.140 |
Why?
| | Middle Aged | 6 | 2020 | 25702 | 0.130 |
Why?
| | Linear Models | 1 | 2015 | 431 | 0.130 |
Why?
| | Quality of Life | 1 | 2020 | 1379 | 0.130 |
Why?
| | Algorithms | 1 | 2021 | 1854 | 0.120 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 819 | 0.120 |
Why?
| | Stents | 1 | 2015 | 386 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2007 | 1213 | 0.110 |
Why?
| | Follow-Up Studies | 2 | 2016 | 3883 | 0.110 |
Why?
| | Male | 6 | 2020 | 42140 | 0.100 |
Why?
| | United States | 1 | 2022 | 6396 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2332 | 0.100 |
Why?
| | Chromosome Positioning | 1 | 2008 | 3 | 0.100 |
Why?
| | Metaphase | 1 | 2008 | 24 | 0.100 |
Why?
| | Anaphase | 1 | 2008 | 20 | 0.090 |
Why?
| | Centrosome | 1 | 2008 | 23 | 0.090 |
Why?
| | Chromosome Segregation | 1 | 2008 | 30 | 0.090 |
Why?
| | Female | 5 | 2020 | 45032 | 0.090 |
Why?
| | Catalysis | 1 | 2008 | 203 | 0.090 |
Why?
| | Cytokinesis | 1 | 2008 | 56 | 0.090 |
Why?
| | Gene Silencing | 1 | 2008 | 183 | 0.090 |
Why?
| | cdc25 Phosphatases | 1 | 2007 | 18 | 0.090 |
Why?
| | Thermodynamics | 1 | 2008 | 309 | 0.090 |
Why?
| | Aged, 80 and over | 2 | 2016 | 6605 | 0.080 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2007 | 52 | 0.080 |
Why?
| | Enzyme Activation | 1 | 2008 | 739 | 0.080 |
Why?
| | Protein Transport | 1 | 2008 | 421 | 0.080 |
Why?
| | beta-Transducin Repeat-Containing Proteins | 1 | 2006 | 4 | 0.080 |
Why?
| | Aged | 4 | 2020 | 18611 | 0.080 |
Why?
| | ras Proteins | 1 | 2007 | 133 | 0.080 |
Why?
| | Fibronectins | 1 | 2006 | 95 | 0.080 |
Why?
| | Ubiquitin | 1 | 2006 | 93 | 0.070 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2004 | 44 | 0.070 |
Why?
| | Pituitary Gland | 1 | 2004 | 102 | 0.070 |
Why?
| | Cell Line | 1 | 2008 | 2620 | 0.060 |
Why?
| | Retrospective Studies | 1 | 2015 | 7798 | 0.060 |
Why?
| | Models, Biological | 1 | 2008 | 1799 | 0.050 |
Why?
| | Monte Carlo Method | 1 | 2021 | 184 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 679 | 0.050 |
Why?
| | Journal Impact Factor | 1 | 2019 | 17 | 0.050 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 191 | 0.050 |
Why?
| | Watchful Waiting | 1 | 2019 | 47 | 0.050 |
Why?
| | Adult | 2 | 2016 | 26137 | 0.050 |
Why?
| | Phantoms, Imaging | 1 | 2021 | 428 | 0.050 |
Why?
| | Radiotherapy | 1 | 2020 | 342 | 0.050 |
Why?
| | Postoperative Care | 1 | 2019 | 232 | 0.050 |
Why?
| | Time Factors | 3 | 2019 | 5516 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 875 | 0.040 |
Why?
| | S Phase | 2 | 2007 | 63 | 0.040 |
Why?
| | Logistic Models | 1 | 2019 | 1166 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2020 | 7966 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2020 | 1784 | 0.040 |
Why?
| | Cell Cycle | 2 | 2007 | 522 | 0.030 |
Why?
| | Prospective Studies | 1 | 2020 | 4122 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2007 | 1560 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 1058 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2007 | 2974 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2006 | 2437 | 0.020 |
Why?
| | Mice | 3 | 2007 | 11210 | 0.020 |
Why?
| | G2 Phase | 1 | 2007 | 32 | 0.020 |
Why?
| | Caveolin 1 | 1 | 2006 | 25 | 0.020 |
Why?
| | Lysosomes | 1 | 2006 | 126 | 0.020 |
Why?
| | Ultraviolet Rays | 1 | 2006 | 194 | 0.020 |
Why?
| | Receptors, Pituitary Hormone-Regulating Hormone | 1 | 2004 | 3 | 0.020 |
Why?
| | Receptors, Neuropeptide | 1 | 2004 | 8 | 0.020 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2004 | 7 | 0.020 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2004 | 23 | 0.020 |
Why?
| | Bromodeoxyuridine | 1 | 2004 | 60 | 0.020 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2004 | 25 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 410 | 0.020 |
Why?
| | Coloring Agents | 1 | 2004 | 71 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 70 | 0.020 |
Why?
| | G1 Phase | 1 | 2004 | 65 | 0.020 |
Why?
| | Transgenes | 1 | 2004 | 182 | 0.020 |
Why?
| | Immunoblotting | 1 | 2004 | 279 | 0.020 |
Why?
| | Fibroblasts | 1 | 2007 | 732 | 0.020 |
Why?
| | Estrogens | 1 | 2004 | 190 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2006 | 377 | 0.020 |
Why?
| | Adenoviridae | 1 | 2004 | 348 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2004 | 568 | 0.020 |
Why?
| | Animals | 3 | 2007 | 27167 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2007 | 3200 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1830 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2004 | 1962 | 0.010 |
Why?
| | Rats | 1 | 2006 | 4351 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2004 | 2008 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 1622 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2004 | 1481 | 0.010 |
Why?
| | Apoptosis | 1 | 2004 | 1782 | 0.010 |
Why?
|
|
Osmundson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Physical Neighbors People whose addresses are nearby this person. _
|